Get the most recent information regarding events and developments at the Novartis Pavillon. This page highlights current announcements related to our public programs and the ongoing Wonders of Medicine exhibition. Please check our official channels for real-time updates as schedules are subject to change.
Novartis R&D leaders share insights into the next decade of scientific advancement across oncology, neuroscience, and immunology. This update highlights the innovative platforms and strategies being deployed to address complex patient needs and improve long-term health outcomes.
Novartis has achieved a major milestone with the FDA's traditional approval of Fabhalta (iptacopan) for treating primary IgA nephropathy. This breakthrough medication, which works by targeting the alternative complement pathway, has shown a significant ability to slow the decline of kidney function in adult patients. This development highlights ongoing progress in nephrology and the future of targeted medical research.
Celebrating the 30th anniversary of the Novartis merger, this retrospective looks back on a legacy spanning 250 years of scientific discovery. Discover how a commitment to reimagining medicine continues to drive breakthroughs in healthcare and patient treatment today.
Novartis has announced a strategic agreement to acquire the UK-based biotechnology company Myricx Bio. This partnership aims to advance next-generation antibody-drug conjugate (ADC) therapies by leveraging novel NMTi payload technology to address treatment resistance in solid tumors.
The European Commission has officially approved Itvisma® as a new gene replacement therapy for patients with spinal muscular atrophy (SMA). This one-time treatment option is designed to address the underlying genetic cause of the disease in children two years and older, teens, and adults. The approval marks a significant development in the available therapeutic choices for those managing SMA across the European Union.
Novartis has announced promising results from the phase 3 RemIND trial, showing the potential of Rhapsido (remibrutinib) as a targeted therapy for chronic inducible urticaria (CIndU). The study demonstrated that the treatment provides significant symptom relief for patients, offering a new potential option for those whose condition remains inadequately controlled by standard antihistamines.
Novartis has announced promising results from the FORTITUDE Phase I/II clinical trial for del-brax, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD). This update underscores the ongoing commitment to advancing neurological science and finding potential disease-modifying therapies. Visitors to the Novartis Pavillon can learn more about how cutting-edge research and drug development are shaping the future of global healthcare.
Novartis R&D leaders share insights into the next decade of scientific advancement across oncology, neuroscience, and immunology. This update highlights the innovative platforms and strategies being deployed to address complex patient needs and improve long-term health outcomes.
Celebrating the 30th anniversary of the Novartis merger, this retrospective looks back on a legacy spanning 250 years of scientific discovery. Discover how a commitment to reimagining medicine continues to drive breakthroughs in healthcare and patient treatment today.
Novartis has announced a strategic agreement to acquire the UK-based biotechnology company Myricx Bio. This partnership aims to advance next-generation antibody-drug conjugate (ADC) therapies by leveraging novel NMTi payload technology to address treatment resistance in solid tumors.
Novartis has announced promising results from the phase 3 RemIND trial, showing the potential of Rhapsido (remibrutinib) as a targeted therapy for chronic inducible urticaria (CIndU). The study demonstrated that the treatment provides significant symptom relief for patients, offering a new potential option for those whose condition remains inadequately controlled by standard antihistamines.
Novartis R&D leaders share insights into the next decade of scientific advancement across oncology, neuroscience, and immunology. This update highlights the innovative platforms and strategies being deployed to address complex patient needs and improve long-term health outcomes.
Novartis has announced a strategic agreement to acquire the UK-based biotechnology company Myricx Bio. This partnership aims to advance next-generation antibody-drug conjugate (ADC) therapies by leveraging novel NMTi payload technology to address treatment resistance in solid tumors.
The European Commission has officially approved Itvisma® as a new gene replacement therapy for patients with spinal muscular atrophy (SMA). This one-time treatment option is designed to address the underlying genetic cause of the disease in children two years and older, teens, and adults. The approval marks a significant development in the available therapeutic choices for those managing SMA across the European Union.
Locate prestigious art institutions and heritage sites easily.
Streamline your search for cultural landmarks in Basel. Identify historical archives, fine art hubs, and scientific collections tailored to your specific curiosity. Access essential details for every venue to coordinate your upcoming visit.
